Devimistat Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Devimistat Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 18 September 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Executive recommendation: CONDITIONAL GO
Decision memo
Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.
The central underwriting question is whether Devimistat can convert its Small molecule drug profile and PDC complex biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Devimistat (query alias: Devimistat) |
|---|---|
| Modality / target | Small molecule drug; PDC complex; PDC complex inhibitors, TCA cycle inhibitors |
| Highest global status | Phase 2 |
| Originator | Cornerstone Pharmaceuticals, Inc. |
| Active developers | Northwestern University, Cornerstone Pharmaceuticals, Inc., The Case Comprehensive Cancer Center |
The MCP disease footprint includes Advanced Colorectal Adenocarcinoma, Advanced Gastroesophageal Junction Adenocarcinoma, Advanced Lung Adenocarcinoma. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| NCT06518538 | Phase 2 | Withdrawn | 0 | Primary endpoint not disclosed in English source |
| NCT05926206 | Phase 1/2 | Withdrawn | 0 | Primary endpoint not disclosed in English source |
| NCT05854966 | Phase 2 | Withdrawn | 0 | Primary endpoint not disclosed in English source |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
Multi-institutional retrospective study of IDH2-mutated cholangiocarcinoma.
Not Applicable; n=40; evaluation: Positive. Reported fields: OS = 16.3 Month ( 12.1 - 28.9); mPFS = 3.9 Month ( 1.1 - 5.1)
A Multi-Center Randomized Phase IB/II Study of Gemcitabine and Cisplatin With or Without CPI-613 as First Line Therapy for Patients With Advanced Unresectable Biliary Tract Cancer (BilT-04)
Phase 1/2; n=75; evaluation: Not stated in English source. Reported fields: Phase 1: Incidence of Dose-limiting Toxicity = 0 Pts
442 | NOVEL DEVIMISTAT RESULTS IN COMPLETE REMISSIONS IN HEAVILY PRE-TREATED BURKITT LYMPHOMA
Phase 2; n=13; evaluation: Negative. Reported fields: CR = 22.0 % ; CR = 22.0 %
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Devimistat addresses Advanced Colorectal Adenocarcinoma, Advanced Gastroesophageal Junction Adenocarcinoma, Advanced Lung Adenocarcinoma. Commercial attractiveness rests on addressable patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The MCP screen returned 3 matched transaction record(s) under the scope “asset-specific.” Partner activity is a market-validation signal, but it does not establish net present value.
5. Transaction precedent and economics
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2020-05-05 | Roswell Park Comprehensive Cancer Center will assess the impact of Rafael Pharmaceuticals' CPI-613, with or without chemotherapy agents, on esophageal cancer cells. | Phase 3 | Financial terms not disclosed |
| 2019-10-17 | NCI will evaluate Rafael's CPI-613 in cytokine independent HTLV-1 associated adult T-cell leukemia/lymphoma. | Phase 3 | Financial terms not disclosed |
| 2019-06-25 | Ono Pharmaceutical will collaborate with Rafael Pharmaceuticals to develop and commercialize CPI-613 in Japan, South Korea, Taiwan, and ASEAN countries. | Phase 3 | US$12.9M upfront; US$150.3M milestones; US$163.2M stated total |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
The milestone feed surfaced a patent-application signal described as “Patent source description not available in English”. The milestone feed surfaced a patent-application signal described as “Therapeutic methods and compositions for treating cancer using devimistat and a fatty acid oxidation inhibitor, a tyrosine kinase inhibitor, a glutaminase inhibitor, and/or a glycolysis inhibitor”. The milestone feed surfaced a patent-application signal described as “Patent source description not available in English”.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights.
7. Principal risks and diligence gates
- Therapeutic index and off-target toxicity
- Resistance biology and biomarker-defined patient selection
- Differentiation from established and emerging standards
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
CONDITIONAL GO
Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 2026-09-18. Counts and status fields may change as source records update.
